Brief: Rapport Therapeutics Presents Rap-219 Focal Onset Seizure Phase 2A Follow-Up Period Results
21/04/2026 23:18
April 21 (Reuters) - Rapport Therapeutics Inc RAPP.O: RAPPORT THERAPEUTICS PRESENTS RAP-219 FOCAL ONSET SEIZURE PHASE 2A FOLLOW-UP PERIOD RESULTS DEMONSTRATING SUSTAINED SEIZURE REDUCTION AT THE 2026 AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING RAPPORT THERAPEUTICS INC: RAP-219 WAS GENERALLY WELL TOLERATED THROUGHOUT TREATMENT AND FOLLOW-UP PERIODS Source text: ID:nGNXc7bNXC Further company coverage: RAPP.O ((Reuters.Briefs@thomsonreuters.com;))